Application of Genetically Altered Models as Replacement for the Lifetime Mouse Bioassay in Pharmaceutical Development

Toxicologic Pathology

Volumn 30, Issue 1, 2002, Pages 135-138

  Alden, Carl ^a   Smith, Peter ^a   Morton, Dan ^b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CARCINOGEN; CHLOROFORM; CHLORPROMAZINE; CLOFIBRATE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIELDRIN; DIETHYLSTILBESTROL; ESTRADIOL; HALOPERIDOL; MANNITOL; MELPHALAN; METHAPYRILENE; ORCIPRENALINE; PHENACETIN; PHENOBARBITAL; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PIRINIXIC ACID; PROTEIN P53; RAS PROTEIN; RESERPINE; SULFAFURAZOLE; SULFAMETHOXAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CANCER MODEL; CANCER RESEARCH; CARCINOGEN TESTING; CONTROLLED STUDY; COOPERATION; DISEASE MODEL; DRUG DEVELOPMENT; EVALUATION; GENETIC MODEL; GENOTOXICITY; HEALTH CARE PLANNING; HETEROZYGOSITY; HORMONAL CARCINOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL COOPERATION; LIFETIME MOUSE BIOASSAY; MOUSE; NONHUMAN; PATHOLOGIST; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SAFETY; TOBACCO; TOBACCO INDUSTRY; TRANSGENIC ANIMAL;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; CARCINOGENS; MICE; MICE, TRANSGENIC; PHARMACOLOGY; RISK ASSESSMENT; TOXICOLOGY;

ANIMALIA; NICOTIANA TABACUM; RODENTIA;

EID: 0036192051     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230252824842     Document Type: Article

References (7)

1. Alden CL, Smith PF, Piper CE, Brej L. (1996). A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol Pathol 24(16): 722-725.
2. Alden CL (2000). Safety assessment for non-genotoxi c rodent carcinogens: Curves, low-dose extrapolation, and mechanisms in carcinogenesis. Human Exper Toxicol 19: 557-560.
3. Contrera JF, Degeorge JJ (1998). In vivo transgenic bioassays and assessment of thecarcinogenic potential of pharmaceuticals. Environ Health Perspect 106(S1): 71-80.
4. Monro A. (1996). Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Exp Toxicol Pathol 48: 155-166.
5. Tennant RW, Stasiewicz S., Mennear J., French JE, Spalding JW (1999). Genetically altered mouse models for identifying carcinogens. In: The Use of Short- and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation, McGregor DB, Rice JM, Venitt S (eds). IARC Scientific Publications No. 146, International Agency for Research on Cancer, Lyon. pp 123-150.
6. ILSI/HESI Alternatives to Carcinogenicity Testing Project. Toxicol Pathol 29: Supplement, 2001.
7. Van Oosterhout JPJ, Van Der L aan JW, De Waal EJ, Olejniczak K., Hilgenfeld M., Schmidt Bass R. (1997). The utility of two rodent species in carcinogenic risk assessment of pharmaceutical s in Europe. Regulatory Toxicol Pharmacol 25: 6-17.